- Alvotech Upsizes Oversubscribed PIPE Transaction to Approximately $175 Million
- JAMP and Alvotech Announce Canadian Approval of SIMLANDI™, a High-Concentration Biosimilar to Humira®, Providing Access to Previously Unavailable Versions in Canada
- AVT02, Alvotech’s Biosimilar to High Concentration Formulation of Adalimumab (Humira®) Approved for Use in European Union
- Alvotech and Oaktree Acquisition Corp. II Announce Merger Agreement to Create a Leading Publicly-Traded Global Biopharmaceutical Company
Oaktree Acquisition II Corp (OACB:NYQ) closed at 9.86, 3.25% above its 52-week low of 9.55, set on Mar 25, 2021.
9.55Mar 25 202111.28Feb 10 2021
Markit short selling activity
|Market cap||559.03m USD|
|EPS (TTM)||-0.0488 |
Data delayed at least 15 minutes, as of Jan 28 2022 21:10 GMT.